Get the Stockscreener App
1.11
2.63%
-0.03
After Hours:
1.12
0.01
+0.90%
Immunic Inc stock is traded at $1.11, with a volume of 422.88K.
It is down -2.63% in the last 24 hours and down -11.20% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$1.14
Open:
$1.17
24h Volume:
422.88K
Relative Volume:
0.61
Market Cap:
$94.77M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.5261
EPS:
-2.11
Net Cash Flow:
$-71.16M
1W Performance:
+13.27%
1M Performance:
-11.20%
6M Performance:
-20.14%
1Y Performance:
-11.90%
1-Day Range:
$1.095
$1.2199
1-Week Range:
$0.96
$1.2199
52-Week Range:
$0.8319
$2.11
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
1.11 | 94.77M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Trading Day Review: Immunic Inc (IMUX) Gains Momentum, Closing at 1.14 - DWinneX
Brokerages Set Immunic, Inc. (NASDAQ:IMUX) Price Target at $13.20 - Defense World
IMUX: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Immunic Inc (IMUX) stock on the rise: An overview - uspostnews.com
Immunic’s (IMUX) Buy Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Has Optimistic View of Immunic FY2025 Earnings - Defense World
HC Wainwright Estimates Immunic’s Q1 Earnings (NASDAQ:IMUX) - Defense World
Immunic, Inc. (NASDAQ:IMUX) Is Expected To Breakeven In The Near Future - simplywall.st
Immunic Stock Price, Quotes and Forecasts | NASDAQ:IMUX - Benzinga
Immunic, Inc. Announces Closing of $5.1 Million Registered Direc - GuruFocus
Immunic Stock Draws Investor Attention On $5.1M Registered Direct Offering: Retail’s On Wait-And-Watch Mode - MSN
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - The Malaysian Reserve
Immunic Closes of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - citybiz
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - Eastern Progress
Immunic Raises $5.1 Million From Direct Stock Offering - marketscreener.com
Immunic Lands Strategic $5.1M Financing Deal: Aberdeen Investments Takes Lead Position - Stock Titan
Immunic closes $5.1M placement - Proactive financial news
Immunic announces pricing of $5.1M registered direct offering - MSN
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direc - GuruFocus
Immunic Announces $5.1 Million Securities Purchase Agreement - MSN
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments | IMUX Stock News - GuruFocus
Immunic sets $5.1 million stock offering price By Investing.com - Investing.com Canada
Immunic sets $5.1 million stock offering price - Investing.com Australia
Immunic announces pricing of $5.1M direct offering to support clinical pipeline - Proactive financial news
Immunic Announces Pricing Of $5.1 Million Registered Direct Offering - marketscreener.com
Immunic Lands $5.1M Institutional Backing: Aberdeen Investments Takes Major Stake - Stock Titan
Critical Survey: Immunic (NASDAQ:IMUX) vs. Quoin Pharmaceuticals (NASDAQ:QNRX) - Defense World
What is Leerink Partnrs’ Estimate for Immunic Q1 Earnings? - Defense World
Immunic (NASDAQ:IMUX) Earns “Buy” Rating from D. Boral Capital - The AM Reporter
Immunic (NASDAQ:IMUX) Given “Buy” Rating at D. Boral Capital - Defense World
Immunic to present at AAN 2025 and German Biotech Days in April - Proactive financial news
Immunic, Inc. to Participate in Scientific and Industry Conferences in April - The Malaysian Reserve
Immunic's Game-Changing MS Treatment Takes Center Stage at Two Global Conferences - Stock Titan
IMMUNIC, INC. SEC 10-K Report - TradingView
Immunic CMO discusses significance of MS Awareness Month; progress with treatment - Proactive financial news
Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average PT from Brokerages - Defense World
Immunic Therapeutics: Interview With CEO Dr. Daniel Vitt About The Inflammatory And Autoimmune Diseases Therapy Company - Pulse 2.0
180 Life Sciences (NASDAQ:ATNF) versus Immunic (NASDAQ:IMUX) Head to Head Comparison - Defense World
Immunic (NASDAQ:IMUX) Now Covered by Analysts at William Blair - Defense World
Immunic (NASDAQ:IMUX) Now Covered by William Blair - The AM Reporter
William Blair Initiates Coverage of Immunic (IMUX) with Outperform Recommendation - Nasdaq
William Blair sees Immunic stock outperforming on RMS therapy By Investing.com - Investing.com Australia
How did Immunic Inc (IMUX) fare last session? - uspostnews.com
William Blair sees Immunic stock outperforming on RMS therapy - Investing.com
Companies Like Immunic (NASDAQ:IMUX) Could Be Quite Risky - Yahoo Finance
William Blair Initiates Immunic at Outperform With $6.80 Price Target - MarketScreener
Buy Rating on Immunic Driven by Promising CALLIPER Study Outcomes and Market Opportunities in Progressive Multiple Sclerosis - TipRanks
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):